Improved survival in COVID-19 related sepsis and ARDS treated with a unique "triple therapy" including therapeutic plasma exchange: A single center retrospective analysis.
Philip KeithRebecca Inez Caldino BohnTrung NguyenL Keith ScottMonty RichmondMatthew DayCarol ChoeLinda PerkinsRebecca BurnsideRichard PykeBen RikardAmanda GuffeyArun SainiH J ParkJoseph CarcilloPublished in: Journal of clinical apheresis (2024)
Our analysis shows that early triple therapy, defined as high-dose methylprednisolone, TPE, and timely invasive mechanical ventilation within the first 96 hours of admission, may improve survival in critically ill septic patients with ARDS secondary to COVID-19 infection. Further studies are needed to define specific phenotypes and characteristics that will identify those patients most likely to benefit.
Keyphrases
- mechanical ventilation
- acute respiratory distress syndrome
- high dose
- intensive care unit
- end stage renal disease
- extracorporeal membrane oxygenation
- newly diagnosed
- acute kidney injury
- ejection fraction
- coronavirus disease
- respiratory failure
- sars cov
- emergency department
- chronic kidney disease
- peritoneal dialysis
- prognostic factors
- free survival
- stem cells
- stem cell transplantation
- mesenchymal stem cells
- drug induced
- septic shock
- case control
- patient reported